newsSeptember 11, 2012
Allon’s CEO presenting at 2012 Rodman and Renshaw Global Conference
VANCOUVER, B.C.— Allon Therapeutics Inc.(TSX: NPC) President and CEO Gordon McCauleywill present an update of the Company’s business progress on Tuesday, September 11 at the Rodman and Renshaw Annual Global Investment Conferencein New York City.
McCauley’s presentation will include an update of the Company’s programs, including its pivotal Phase 2/3 clinical trial evaluating lead neuroprotective drug candidate, davunetide, as a potential treatment for progressive supranuclear palsy(PSP), a rapidly progressing and fatal degenerative brain disease.
The fully enrolled pivotal trial is proceeding under a Special Protocol Assessment with the U.S. Food and Drug Administration and is expected to complete patient dosing and release top-line data in Q4 2012. It is being conducted at leading medical institutions in the United States, Canada, the United Kingdom, France, Germany, and Australia. Details can be found atclinical trials.gov.
The live webcast may be viewed at 12:40 p.m. PDT (3:40 p.m. EDT) at https://www.wsw.com/webcast/rrshq22/npc.cn. The presentation will be immediately archived and available for viewing for three months from the Company’s website at https://www.allontherapeutics.com/corporate/news/events-and-webcasts/.
Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors.